New Site Part of Pfizer Commitment to Enhanced Transparency for Investors
               As Well As Scientific and Medical Communities

    NEW YORK, Dec. 20 /PRNewswire-FirstCall/ -- Pfizer announced today it
is launching an on-line site where the progress of compounds in its
research and development pipeline will be made available to investors, plus
the scientific and medical communities, and regularly updated.
    The new site provides details of Pfizer's largest-ever pipeline and
innovative research in cancer, heart disease, diabetes, neurological and
infectious diseases, and many other disease areas. The site includes
clinical programs from Phase I compounds to late-stage medicines under
regulatory review plus recently-approved products. It is now available at
http://www.pfizer.com/pipeline.
    "Today's posting will provide investors as well as the scientific and
medical communities with more detail on our pipeline than ever before, as
well as the ability to see updates on our progress," said Dr. John
LaMattina, President of Pfizer Global Research and Development. "We have
the largest and most diverse pipeline in our history. One of our most
important business priorities is bringing these compounds forward so that
they reach the patients who need them and drive our long-term growth. We
have set specific and realistic goals for introducing a steady stream of
new products in the years ahead -- four internally developed products by
2011 plus two externally acquired products by 2010 -- and we look forward
to reporting on our progress."
    He continued, "We have more experimental medicines and clinical
programs than ever before in our history, with potential breakthrough
therapies across many major therapeutic areas. By making this information
available on-line, we will give investors, physicians and patients deeper
insights into our goals, the scope and progress of clinical trials for
individual compounds, and our overall mission to fight and cure disease."
    Today's launch follows the company's commitment, made to analysts and
investors at its November 30 R&D briefing, to make available pipeline
details before the end of this year. At that briefing the company described
30 research programs, with more than half highlighted for the first time.
Pfizer's pipeline has nearly 250 preclinical and clinical programs,
including 169 new molecular entities.
    Descriptions of Pfizer's eleven major therapeutic areas and 63 diseases
that are at the center of its research efforts are also provided on the new
website, which will be updated twice a year.
    DISCLOSURE NOTICE: The information contained in this release is as of
December 20, 2006. The Company assumes no obligation to update any forward-
looking statements contained in this release as a result of new information
or future events or developments.
    This release contains forward-looking information about the
introduction of new products that involves substantial risks and
uncertainties. A description of these risks and uncertainties can be found
in the Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2005 and in its reports on Forms 10-Q and 8-K.

Link to this page:

  

http://www.prnewswire.com/comp/688250.html/
CONTACT:
Stephen Lederer, +1-860-732-9783

---

---

Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996- PR Newswire Association LLC. All Rights Reserved.
A United Business Media company.